logo-loader
viewIXICO PLC

Notice of Results

/**/ h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:14.0pt;font-family:"Calibri","sans-serif";color:#31849B;font-weight:bold;}h2{margin-top:10.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:13.0pt;font-family:"Calibri","sans-serif";color:#31849B;font-weight:bold;}h3{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;line-height:115%;font-size:13.0pt;font-family:"Calibri Light","sans-serif";font-weight:bold;}h4{margin-top:2.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Cambria","serif";color:#365F91;font-weight:normal;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ai{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ai{}p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}span.bf{color:black}p.ad,li.ad,div.ad{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}span.bi{font-family:"Arial","sans-serif";font-size:11.0pt;font-family:"Calibri","sans-serif"}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.bk{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;background:white}span.bl{color:black}p.bm{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal} p.bn{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -12.5pt; margin-top: 0cm; text-align: justify}table.bo{margin-left:-5.4pt;border-collapse:collapse}td.aw{width:286.65pt;padding:0cm 5.4pt 0cm 5.4pt}p.bp{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 11.0pt}span.ay{font-size: 10.0pt;line-height:115%;color:black}td.at{width:142.55pt;padding:0cm 5.4pt 0cm 5.4pt}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;text-align:justify}span.av{font-size:10.0pt;line-height:115%;color:black}p.br{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt}span.as{font-size:10.0pt; line-height:115%;color:black} p.bs{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 11.0pt; text-align: justify}p.bt{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify}span.bu{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.bv{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; text-align: justify}span.am{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.ac{}span.bw{color:black}span.bx{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.bd{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.by{color:blue;text-decoration:underline;font-family: "Calibri","sans-serif"; font-size: 11.0pt; text-decoration: none} /**/
RNS Number : 2848U
IXICO plc
22 November 2019
 

 22 November 2019

IXICO plc

("IXICO" or the "Company")

 

Notice of Results

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, will announce its final results for the year ended 30 September 2019 on Wednesday, 4 December 2019.

 

Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 GMT on the day of the results.  Further details will be provided on request.

 

For further information please contact:

 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer




Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales)




Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Manel Mateus


[email protected]


 

About IXICO

 

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease. 

 

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

 

More information is available on www.IXICO.com

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORBRBDBUSDBGCB

Quick facts: IXICO PLC

Price: 74.8084

Market: AIM
Market Cap: £35.09 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IXICO PLC reports first year of profitability 'well ahead of expectations'

IXICO PLC's (LON:IXI) Giulio Cerroni sat down with Proactive London's Andrew Scott after reporting its first year of profitability since its admission to AIM . For the year ended 30 September, the neuroscience analytics firm swung to an underlying (EBITDA) profit of £500,000 from a £600,000...

1 week, 5 days ago